Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2012-002067-10-NL
EUCTR2012-002067-10-NLActive, not recruitingNot Applicable

Mesenchymal stromal cells for treatment of drug resistantpediatric Juvenile idiopathic arthritis - MSC-JIA

niversity Medical Center Utrecht0 sitesStarted: September 24, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients (4-18 years of age) diagnosed with juvenile idiopathic arthritis according to the ILAR-criteria with active arthritis resistant to intra-articular steroids and systemic use of methotrexate and for whom no on-label indication exists for (not yet used) biologicals. The patient is followed for adverse events via the Pharmachild database.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 6
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Concurrent use of biological response modifiers.
  • •Concurrent infection, febrile illness or malignancy.

Investigators

Similar Trials

Recruiting
Not Applicable
Mesenchymal stromal cells for treatment of drug resistantpediatric juvenile idiopathic arthritisjuvenile idiopathic arthritis
NL-OMON21350niversity Medical Center Utrecht6
Active, not recruiting
Not Applicable
Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial - MSC-GvHDGraft versus Host disease GvHD steroid resistant
EUCTR2008-007869-23-ITAZIENDA OSPEDALIERA SAN GERARDO DI MONZA
Active, not recruiting
Not Applicable
se of mesenchymal cells for the treatment of patients with respiratory syndrome caused by new coronavirus
RBR-3fz9yrPaulo Roberto Slud Brofman
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.
EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
Terminated
Phase 1
se of mesenchymal stromal cells for Graft-versus-host disease after stem cell transplantatioGraft vs Host DiseaseT86.0
RBR-7s99ksfHospital de Clínicas da Universidade Federal do Paraná - HCUFPR